Kadmon Reveals A Bit Of Its Hand To Investors
This article was originally published in The Pink Sheet Daily
Kadmon CEO Sam Waksal - the former CEO of ImClone - laid out the startup's ambitious pipeline during the Jeffries Healthcare Conference.
You may also be interested in...
Vertex Pharmaceuticals' Incivek (telaprevir) has cleared FDA with labeling advantages that should enable it to win a majority of patients in the battle against Merck's competing protease inhibitor for hepatitis C, Victrelis (boceprevir).
Deal with Valeant brings development and commercialization rights to ribavirin analog that could have better safety profile for anemia.
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.